These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15287820)

  • 1. Technological advances in high-throughput screening.
    Liu B; Li S; Hu J
    Am J Pharmacogenomics; 2004; 4(4):263-76. PubMed ID: 15287820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR-based screening methods for lead discovery.
    Vogtherr M; Fiebig K
    EXS; 2003; (93):183-202. PubMed ID: 12613177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High impact technologies for natural products screening.
    Koehn FE
    Prog Drug Res; 2008; 65():175, 177-210. PubMed ID: 18084916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Origin and evolution of high throughput screening.
    Pereira DA; Williams JA
    Br J Pharmacol; 2007 Sep; 152(1):53-61. PubMed ID: 17603542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).
    Schröter T; Minond D; Weiser A; Dao C; Habel J; Spicer T; Chase P; Baillargeon P; Scampavia L; Schürer S; Chung C; Mader C; Southern M; Tsinoremas N; LoGrasso P; Hodder P
    J Biomol Screen; 2008 Jan; 13(1):17-28. PubMed ID: 18227223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current in vitro high throughput screening approaches to assess nuclear receptor activation.
    Raucy JL; Lasker JM
    Curr Drug Metab; 2010 Nov; 11(9):806-14. PubMed ID: 21189134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New fluorescence techniques for high-throughput drug discovery.
    Jäger S; Brand L; Eggeling C
    Curr Pharm Biotechnol; 2003 Dec; 4(6):463-76. PubMed ID: 14683438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High throughput pharmacology for drug discovery].
    Ozaki H; Imaizumi Y; Oishi K; Kohama K
    Nihon Yakurigaku Zasshi; 2001 Sep; 118(3):187-96. PubMed ID: 11577459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators.
    Trivedi S; Dekermendjian K; Julien R; Huang J; Lund PE; Krupp J; Kronqvist R; Larsson O; Bostwick R
    Assay Drug Dev Technol; 2008 Apr; 6(2):167-79. PubMed ID: 18078380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.
    Du Y; Nikolovska-Coleska Z; Qui M; Li L; Lewis I; Dingledine R; Stuckey JA; Krajewski K; Roller PP; Wang S; Fu H
    Assay Drug Dev Technol; 2011 Aug; 9(4):382-93. PubMed ID: 21395401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID NMR Methods in ligand-receptor interactions.
    Zartler ER; Yan J; Mo H; Kline AD; Shapiro MJ
    Curr Top Med Chem; 2003; 3(1):25-37. PubMed ID: 12577989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions.
    Huber W
    J Mol Recognit; 2005; 18(4):273-81. PubMed ID: 15997470
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.